Tirzepatide

Also known as: Mounjaro, Zepbound, LY3298176, Dual GIP/GLP-1 Agonist

Metabolic

Approved

Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist that has shown superior weight loss and glycemic control compared to semaglutide in head-to-head trials. It is the first drug in the 'twincretin' class and has become a cornerstone of modern obesity pharmacotherapy.

Regulatory & Approval Status

FDA Approved

Tirzepatide is FDA-approved under the brand names Mounjaro for type 2 diabetes and Zepbound for chronic weight management.

Information compiled from FDA compounding guidance and public regulatory sources. For research and educational purposes only; not medical advice.

Unlock the complete research profile

Create your free CertifiedTide account to access full compound details, mechanisms, safety data, and research tools.